Background. Expected value of perfect information (EVPI) calculations are increasingly performed to guide and underpin research recommendations. An EVPI value that exceeds the estimated cost of research forms a necessary (although not sufficient) condition for further research to be considered worthwhile. However, it is unclear what factors affect researchers' recommendations and whether there is a notional threshold of positive returns below which research is not recommended. The objectives of this study were to explore whether EVPI and other factors have a bearing on research recommendations and to assess whether there exists a threshold EVPI below which research is typically not recommended. Methods. A systematic literature review was undertaken to identify applied EVPI calculations in the health care field. Study characteristics were extracted, including funder, location, disease group, publication year, primary language, and outcome measure. Population EVPI values and willingness-to-pay thresholds were also extracted alongside verbatim text excerpts describing the authors' research recommendations. Recommendations were classified according to whether further research was recommended (a positive recommendation) or not (negative). Factors affecting the likelihood of a positive recommendation were examined statistically using logistic regression and visually by plotting the results in graphs. Results and Conclusions. Eighty-six articles were included, of which 13 suggested no further research, 66 recommended further research, and 7 gave no recommendation. EVPI appears to be a key driver of researchers' recommendations for further research. Disease area, funder, study location, publication year, and outcome may have a bearing on recommendations, although none of these factors reached statistical significance. A threshold EVPI value below which research is typically not recommended was found at around £1.48 million.
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EVPI has the potential to be used as a means of assessing research priorities in a fund-limited research environment. 17 If the cost of obtaining further information (via a randomized controlled trial, for example) exceeds the EVPI, there is little justification for proceeding with research, and decision makers can be confident that they could not make a better decision by waiting. Thus, the EVPI exceeding the cost of running a trial is a necessary condition that must be fulfilled before research can be considered potentially worthwhile and represents a maximum amount that a rational decision maker should spend on further research. 18 It should be noted that a high EVPI value is not a sufficient condition for advising further research, and firm recommendations in favor of further research based on the EVPI value alone are inappropriate. More information from expected value of sample information (EVSI) studies is required to determine whether a particular piece of research should be conducted. 19 However, a recent review of expected value of information (EVI) methods and applications found that despite EVSI being the metric of choice for informing decision making, applied EVSI calculations are rarer than applied EVPI values. 20 It is likely that this imbalance arises because EVSI is both conceptually and computationally complex, while EVPI analysis is relatively straightforward to conduct. Given that different trials are anticipated to cost different amounts, and the measure that should be used strictly to distinguish between those trials worth funding is EVSI, it is possible to see different recommendations for similar values of EVPI. For example, Forbes and others 21 recommended further research on the basis of an EVPI value of £10.7 million, while Rogowski and others 22 did not recommend further research with an EVPI value of £10.76 million. It is also likely that considerations other than the magnitude of EVPI (e.g., disease area of interest, type of outcome used) may be taken into account in making research recommendations.
With this in mind, we conducted a systematic literature review to identify applied VOI studies with the aim of investigating how researchers interpret calculated EVPI values when making research recommendations. The study explores whether there exists an empirical magnitude of EVPI below which no recommendation for further health research is typically made (i.e., whether there is an empirical threshold), looks into the degree of consistency across the literature in the recommendations for further research for a given level of EVPI, and investigates whether different factors, including disease area, country, and measure of outcome, may influence recommendations. We aim to observe what is happening in practice, in order to improve transparency in discussions around decision making.
METHODS
The review was carried out in line with widely used recommendations for undertaking systematic literature reviews 23 and aimed to retrieve applied studies reporting EVPI calculations. Prior to the publication of the methodological description by Claxton and Posnett 14 in 1996, EVPI calculations were rarely reported in health economics; therefore, conducting the search from 1990 covers the probable extent of relevant literature. From April 2011, the Cancer Drugs Fund came into force in England 24 ; this altered commissioning attitudes to the acceptable threshold for funding particular cancer treatments and therefore has the potential to alter approaches to funding research. Therefore, the period searched was limited to 1990-2010 to avoid adding complications to possible interpretations.
Search Strategy
As EVPI calculations are not routinely reported in abstracts and keywords, two different approaches to searching the literature were followed. In the first, standard bibliographic databases were searched with relatively broad search terms, while in the second, full-text searching was performed with tightly defined search terms. The bibliographic databases Medline, EMBASE, CINAHL, Web of Science, and The Cochrane Library (which includes the Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Cochrane Methodology Register, Database of Abstracts of Reviews of Effects, Health Technology Assessment Database, and the National Health Service Economic Evaluation Database [NHS EED]) were searched using a combination of search terms and wildcards to cover the range of different value of information phrases. Adding the qualifier ''AND cost'' significantly improved the specificity of the searches without reducing the sensitivity. Full-text searching was undertaken via the websites of the journal publishers and suppliers AdisOnline, HighWire Press, IngentaConnect, Cambridge Journals Online, and ScienceDirect and the UK Health Technology Assessment (HTA) site, covering the significant journals in health economics. Fulltext searches were also conducted using the Google Scholar search engine. Details of the searches undertaken are given in Appendix 1 (available online).
Inclusion Criteria
Articles were included if they reported calculations of one or more measures of the population EVPI, were undertaken as part of an applied study assessing health care interventions, and were peerreviewed publications. Articles were excluded if the EVPI calculation was carried out purely to illustrate a methodological point (e.g., if the data used were manipulated to disguise their origin), the intervention was an environmental health application, or the article was not written in English.
Selection Process
Abstracts of identified studies were screened by one author (J.T.). A 10% sample of the abstracts was screened by two reviewers (L.A. and J.T.) to check for accuracy and consistency; disagreements were resolved by discussion. Some articles without EVPI calculations were eliminated by consulting health economic assessments in the NHS EED or contacting the author.
For the remaining abstracts, full-text versions were obtained and screened electronically (by J.T.) where possible. Multiple pdf file search functionality was used to search for the word ''perfect'' in order to eliminate articles that would not contain an EVPI calculation. Nonsearchable pdfs were identified, and these articles were manually scanned for EVPI calculations. For articles containing the word ''perfect,'' the context was examined to eliminate irrelevant material. A second screening cycle was applied to those articles that either did not contain the word ''perfect'' or contained it in an irrelevant context by searching for the word ''information.'' A final screening process was undertaken by reading the full text and eliminating articles that did not describe an applied EVPI calculation. Some studies were reported twice; only the most recently published article was included to maximize the likelihood of a full report. However, the earlier report was used to supply additional details where necessary.
Data Extraction
For each study that met the inclusion criteria, extracted information included background characteristics such as publication year, funder, location, and disease group based on ICD-10 chapter heading. Both individual and population EVPI values were extracted, along with the willingness-to-pay (WTP) threshold (i.e., the hypothetical value that society is willing to pay for an additional unit of health outcome), outcome measure, and currency. The time frame over which the technology was expected to be useful was also noted. Where multiple EVPI values were cited, a pragmatic approach to choosing a single value was taken; for example, a value at a WTP of £30,000 (or other commonly cited WTP values) was taken where possible, and EVPI values were read from graphs if necessary. Finally, brief text excerpts describing the interpretation of the values, recommendations based on the values, and research prioritization comments were extracted verbatim.
The extracted texts were classified according to whether the recommendation was for or against further research (i.e., positive or negative), on an ordinal scale of recommendations. The scale ran from ''beneficial'' to do further research (e.g., if the technique was said to warrant further research or further research was justified) through ''probably beneficial'' (e.g., if further research was considered likely to be worthwhile), ''possibly beneficial'' (if phrases such as ''could be cost-effective'' were used), ''possibly not beneficial'' (e.g., if research ''may not be'' costeffective), ''probably not beneficial'' (e.g., if research was considered unlikely to represent an efficient use of resources) and ''not beneficial'' to do further research (e.g., if it was stated that research would not be justified).
Extracted data were used to classify the type of research funder. Population EVPI and WTP values were converted to sterling using Bank of England exchange rates, taking the value at 31 December (or closest preceding day) of the relevant cost year of the study, or the publication year if unavailable. 25 Owing to the complex nature of EVPI calculations with costs bound up in WTP thresholds and the lack of consistent reporting of cost year, it was not possible to convert EVPI values to a common cost year. The quality of the articles was not formally assessed and did not form one of the exclusion criteria because we were interested in how authors responded to the values that they found rather than whether the EVPI calculations were correctly derived. Therefore, articles with methodological limitations were not excluded on that basis alone. For example, where an inappropriately large population had been used to derive a population EVPI resulting in a hugely inflated value, the study was included in the analysis because a recommendation was still made and flowed logically from the value calculated.
Statistical Modeling
Extracted data provided the basis for exploring possible relationships between authors' research recommendations and various factors, such as country that the study relates to, study funder, disease area, year of publication, and magnitude of EVPI. As a first step, we used the data to consider graphically how these factors may affect research recommendations. In addition, the impact of these factors on the dichotomous ''recommend/not recommend'' outcome variable was explored using logistic regression. Briefly, logistic regression models the effect of one or more explanatory variables and interaction terms (here, various factors) on the odds of a dichotomous dependent variable (here, recommend/not recommend). Different interaction terms were considered on the premise that these have a plausible modifying effect on the outcome variable (e.g., interaction between EVPI and country, assuming that EVPI may differ according to the country that research relates to). Different model specifications were considered using stepwise selection (forward selection and backward elimination) and hierarchical regression. An unrestricted (full) model containing all the available variables was compared with several nested models using the likelihood ratio (LR) test and the Akaike (AIC) and Bayesian (BIC) information criteria. 26 An empirical threshold EVPI value was calculated at the point where the probability of a positive recommendation is 0.5, holding any covariates in the model fixed at their baseline values. 27 Statistical and graphical analyses were performed using Stata 11. 28 
RESULTS
The bibliographic database searches identified 2078 potentially relevant articles, while a further 560 articles were identified via full-text searches. Following deduplication, 2497 abstracts required screening. Screening by two reviewers of a 10% sample (250 abstracts) resulted in good agreement on inclusion (k = 0.72). Inspection of the abstracts, consultation of the NHS EED, and author contacts led to 2032 articles being eliminated from consideration, including 13 articles that were written in a language other than English.
Full-text versions of 465 articles were obtained, and 322 were eliminated electronically or by scanning hard copies. The remaining 143 articles underwent a close reading of the full text, and data extraction was undertaken for 86 articles, listed in Appendix 2 (online). Extracted data are presented in Appendix 3 (online). A flowchart describing the systematic review process is given in Figure 1 .
Background Characteristics
The publications included were drawn from a wide range of journals. Higher numbers of EVPI calculations have been observed in recent years. Nine studies were carried out alongside trials, with the remainder being pure modeling studies. Where stated, time frames over which the technology under study was expected to remain useful varied from 1 to 30 years, with 38 out of 86 studies opting for 10 years. WTP thresholds for quality-adjusted lifeyear (QALY) outcomes ranged from £500 to nearly £80,000. Seven articles reported EVSI calculations in addition to EVPI results. Other key characteristics of the included studies are listed in Table 1 .
Research Recommendations
Categorical recommendations were rare, with only a few explicitly using the term ''recommend''; however, many were implicit. Where an absolute, rather than a comparative, value judgment was applied, the EVPI was described as ''low,'' ''small,'' ''high,'' ''large'' or ''substantial.'' Of the 86 included articles, 13 suggested no further research, while 66 were more positive (10 implicitly through parameter research recommendations, 2 on the basis of factors other than VOI results and the remainder on the basis of the EVPI value). Seven made no recommendation. The costs of carrying out research-an essential requirement for making a robust recommendationwere not frequently assessed, with few articles making reference to actual figures. These estimates varied substantially (e.g., as low as e200,000 [£172,000] and as high as $27.1 million [£17.5 million] for a phase III clinical trial), as might be expected for varying trial designs and settings.
The classification of recommendations is illustrated in Figure 2 . Owing to the extensive range of EVPI values observed, the graphs are plotted on a natural logarithmic scale. For presentation purposes, the scale has been truncated and study numbers are omitted. The graph indicates that stronger belief that no further research should be pursued is clustered at lower EVPI values, while a strong belief that research should be carried out tends to be more common toward higher EVPI values. Collapsing the data into binary categories of no further research (including all 3 negative categories) and any other recommendation ( Figure 3 ) suggests a cutoff point around an EVPI value of £250,000, below which research was not typically recommended. Between £250,000 and £2 million, recommendations were variable, 
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while EVPI values over £2 million did not typically attract recommendations against further research.
Statistical Analysis
The statistical analysis showed EVPI to be the only significant predictor (P = 0.007) of research recommendations. No interaction terms were found to be significant at the 0.05 level. A restricted model containing EVPI as the only explanatory variable (''EVPI only'') fitted the data significantly better than a constant-only (empty) model (Likelihood ratio: 37.8; P \ 0.000). The unrestricted model containing all the available variables (full model) achieved a small, nonsignificant improvement in explanatory strength over the EVPI-only model (Likelihood ratio: 40.85, P = 0.723). Stepwise selection also resulted in a model with EVPI as the only statistically significant parameter at significance levels up to 0.15.
Results of the EVPI-only and full models, in terms of changes in the odds of a positive recommendation for a unit change in each explanatory variable, are given in Table 2 . In the EVPI-only model, an increase in EVPI by £1 million is associated with an increase in the odds of a positive research recommendation by 56% (95% CI 13%-115%, P = 0.007). Predicted values of the probability of a positive recommendation at different values of EVPI are shown in Figure 4 . At levels of EVPI up to £1.48 million, the probability of a study recommending research is less than 0.5. At £1.48 million, the probability of a positive recommendation reaches 0.5 (95% CI 0.29-0.70), indicating that a threshold value above (below) which researchers are more (less) likely to recommend research exists roughly at £1.5 million. For EVPI values between £1.5 and £4 million, the probability is between 50% and 75%, while for higher EVPI values, in excess of £10 million, this probability is over 95%. While not statistically significant, the odds of a positive recommendation as calculated using the full model were higher for studies on neoplasms and studies funded by academic institutions and industry compared with those sponsored by the government or medical charities. The odds of a positive recommendation were lower for studies whose results relate to the UK, for studies that report QALYs, and for studies published after 2007 (Appendix 4, online). Given that none of these variables were statistically significant predictors of the probability of a positive recommendation, we emphasize that the discussion around the findings of the full model is intended to provide indications rather than firm conclusions.
DISCUSSION
Our exploration suggests that recommendations are reasonably consistent with EVPI values, with greater EVPI values attracting more positive recommendations for research. An empirical threshold value of £1.48 million was determined via a statistical analysis, above which the predicted likelihood of a positive recommendation exceeds 0.5. The use of an EVPI value alone to make an explicit firm recommendation to conduct further research would, however, be inappropriate; most positive recommendations also took other factors into account, expressing the recommendation in terms of possible, rather than definite, benefits.
Different factors may have a bearing on the interpretation of EVPI and subsequent recommendations, although none were found to be statistically significant in this study. Neoplasms appear to attract in, and approval for, cancer research may influence authors. In the top 10 therapeutic research areas focused on by pharmaceutical companies, cancer drugs outweigh other areas by a factor of at least 2.5. 30 Cancer research is well supported by multiple funding sources including charitable entities, 31 and authors may be encouraged to make positive research recommendations by the likelihood of receiving research funding. Funding by industry sponsors is associated with the presentation of more positive cost-effectiveness results, a form of publication bias. 32 This study suggests that industry sponsors may be more likely than government sponsors to make positive recommendations based on their VOI results, which may tally well with commercial interests. However, academic sponsors were also more likely than government sponsors to make positive recommendations. Studies published before 2007 are more likely to give positive recommendations, which could be a result of a more cautious stance toward recommending research in a period characterized by policies aimed to contain public expenditure. Although there is a possibility that researchers naturally have a vested interest in recommending further research, this study does not provide any significant evidence to support this idea. Most of the identified studies were carried out with a view to informing treatment and research recommendations in the UK. The preponderance of studies originating from the UK is likely to have arisen as a result of national guidelines, with the National Institute for Health and Care Excellence (NICE) having formally advocated the use of VOI methods in England and Wales in 2004. 33 As Eckermann and others 34 point out, in determining a threshold value of EVPI one needs to consider the costs of undertaking research, which, in turn, depend on the type and size of the proposed research program. The costs of further research can vary significantly. In 2005, clinical trials cost a total of $24 billion in the US, representing a mean cost of just under £3 million per trial, 35 while in the UK £950 million was spent, at an average of approximately £100,000 per trial. 36 However, the reasoning behind making a particular recommendation was rarely related to the actual costs of carrying out research, with few studies explicitly citing these costs. One paper referred to the expected high costs of running a trial in that particular disease area, and the authors were negative about further research even with a relatively high EVPI value of £10.76 million 22 ; the authors also took into account the fact that the drug was likely to come off patent during any trial. Costs that were cited covered a broad range, indicating that there is substantial variability around the estimates of trial costs. However, although not explicitly mentioned, the observed values at which research is typically recommended correspond reasonably well with average costs of running trials; it appears that authors implicitly acknowledge probable trial costs. The region of uncertainty between £250,000 and £2 million, where recommendations were not consistent, very plausibly covers typical trial costs. This potential variation in trial costs means that the ''threshold'' we have identified cannot be extrapolated to be treated as a rule that should be followed in all cases.
The study has both strengths and weaknesses. It represents the first attempt at deriving an empirical threshold value of EVPI. The search strategy was rigorous and thorough in order to identify the applied VOI literature. Owing to the variable quality of the suppliers' Boolean logic implementations and the restriction to English-language articles only, some relevant material may have been overlooked; however, this is not likely to alter the broad conclusions. Material from the gray literature was not sought, and this may have led to the omission of some relevant material. It is not clear whether gray material is more or less likely to influence decision making. However, as the interpretation of EVPI values in terms of further recommendations for research is at the discretion of the researcher, we do not believe it is likely that there is a systematic reason for EVPI values to appear in the gray literature only. The texts examined covered a range of countries and cost years. EVPI values were converted to a common currency but not to a common cost year, which may have affected the observed threshold. However, we do not believe that this limitation would have had a substantial effect on the outcome; recommendations against further research were drawn from a wide range of years, and publication year did not have a significant effect on the likelihood of recommendation. Inevitably, there was a level of subjectivity in the classification schema for the recommendations and also in the decision of which EVPI value to choose when multiple values were given.
CONCLUSIONS
Empirical analysis on the basis of the identified literature suggests that calculated EVPI values are a key driver of researchers' recommendations for further research. Factors other than EVPI, including disease area, funder, study location, publication year, and outcome reported, may have a bearing on recommendations for further research; however, none of them reached statistical significance in the analysis. A threshold EVPI value above which the predicted probability of a positive recommendation exceeds 0.5 was found to be around £1.48 million, although there is much variation around this value.
EVPI should not be seen as a substitute for EVSI, which is a more realistic and informative measure of the value of pursuing real-world sample research. However, we believe that there is a role for EVPI in research prioritization, in providing a simple criterion that can indicate the situations where pursuing further research would be wasteful.
This study offers insights into factors and considerations that may affect recommendations made in light of EVPI values. Unless such factors and considerations are understood and made explicit, there will always be a risk that researchers' recommendations for further studies will be treated as subjective and opaque.
